'Hitchhiking' viral therapy deals a double blow to cancer
Scientists have shown how a promising viral therapy that delivers a double blow to cancer can sneak up on tumours undetected by hitching a ride on blood cells.
The work, led by researchers from the University of Leeds and The Institute of Cancer Research (ICR), reveals how the 'hitch-hiking' virus is shielded from antibodies in the blood stream that might otherwise neutralise its anti-cancer properties.
The findings, from a study in patients, suggest that viral therapies like this can be effectively injected into the bloodstream during routine outpatient appointments - just like standard chemotherapy agents making them potentially suitable for use against a wide range of cancers.
Reovirus is a promising new way of treating cancer that attacks the disease on two fronts. Not only does the virus kill cancer cells directly, but it also triggers an immune response - like a vaccine that helps eliminate residual cancer cells.
Many patient trials of reovirus are currently underway, including several in the UK led by the same University of Leeds and ICR scientists. Up until now, however, doctors have not been sure about the best way to deliver the experimental treatment. Although the virus can be injected directly into tumours, this is a relatively complicated procedure requiring considerable technical expertise. This delivery method also makes it difficult to treat tumours deep within the body, such as the liver, lungs, pancreas, and stomach.
Researchers had been concerned that reovirus might not reach the tumours it was supposed to treat if it was delivered intravenously, like standard chemotherapy agents are. They had expected that antibodies in the blood would mop up and neutralise the virus before it arrived at its intended target.
But now tests on a small group of patients have shown that this is not the case. In fact, not only did the virus stay active during its journey through the bloodstream but it also homed in on cancer cells, ignoring nearby healthy tissue.
University of Leeds' researcher Professor Alan Melcher, who receives funding from Cancer Research UK, jointly led the study. He said: "It seems that reovirus is even cleverer than we had thought. By piggybacking on blood cells, the virus is managing to hide from the body's natural immune response and reach its target intact. This could be hugely significant for the uptake of viral therapies like this in clinical practice."
Dr Kevin Harrington from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, who jointly led the study, said: "Viral treatments like reovirus are showing real promise in patient trials. This study gives us the very good news that it should be possible to deliver these treatments with a simple injection into the bloodstream. It would have been a significant barrier to their widespread use if they could only have been injected into the tumour, but the finding that they can hitch a ride on blood cells will potentially make them relevant to a broad range of cancers. We also confirmed that reovirus was specifically targeting cancer cells and leaving normal cells alone, which we hope should mean fewer side-effects for patients."
The study involved 10 patients with advanced bowel cancer who were due to have surgery on tumours that had spread to the liver. All patients were given up to five doses of the reovirus in the weeks before surgery as outpatients.
Blood tests carried out shortly after treatment found the active virus associated with blood cells. Samples taken later showed that the hitch-hiking virus did not overstay its welcome with the cells and was cleared quickly from the system.
When researchers looked at pieces of tissue removed during surgery up to four weeks later, they found 'viral factories' and active virus in the tumour, but not normal liver. This confirmed that the reovirus had been delivered specifically to the cancer after being injected into the bloodstream.
Dr Julie Sharp, senior science information manager at Cancer Research UK, which part-funded the research, said: "This promising study shows that reovirus can trick the body's defences to reach and kill cancer cells and suggests that it could be given to patients using a simple injection. We look forward to seeing how this research develops and if this could one day become part of standard cancer treatment."
Full details of the work are published today in the journal Science Translational Medicine.
More information: Adair, RA, "Cell Carriage, Delivery, and Selective Replication of an Onocolytic Virus in Tumor in Patients," Science Translational Medicine, 2012.
Journal reference: Science Translational Medicine
Provided by University of Leeds
- The multi-tasking reovirus Feb 08, 2007 | not rated yet | 0
- Macavity wasn't there! How absent reoviruses kill cancer Feb 21, 2011 | not rated yet | 0
- Harmless human virus may be able to boost the effects of chemotherapy Apr 03, 2012 | not rated yet | 0
- Reovirus may be a novel approach to prostate cancer treatment Mar 09, 2010 | not rated yet | 0
- Cedars-Sinai Medical Center opens patient trial of virus that attacks brain cancer cells Apr 16, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
4 hours ago Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.
Cancer 27 minutes ago | not rated yet | 0
(Medical Xpress)—Researchers at the University of Virginia School of Medicine have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts ...
Cancer 52 minutes ago | not rated yet | 0 |
(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.
Cancer 14 hours ago | not rated yet | 0
National Lung Screening Trial (NLST) investigators also conclude that the 20 percent reduction in lung cancer mortality with low-dose computed tomography (LDCT) versus chest X-ray (CXR) screening previously reported in the ...
Cancer 15 hours ago | not rated yet | 0
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage ...
Cancer 18 hours ago | not rated yet | 0 |
(Medical Xpress)—The first symptoms of major depression may be behavioral, but the common mental illness is based in biology—and not limited to the brain.
46 minutes ago | 5 / 5 (1) | 0 |
(Medical Xpress)—Scientists at Emory Vaccine Center have shown that an immune regulatory molecule called IL-21 is needed for long-lasting antibody responses in mice against viral infections.
40 minutes ago | not rated yet | 0 |
Human breastmilk responds quickly to protect the child when there is an infection in mothers or babies, according to new international research led by The University of Western Australia.
52 minutes ago | not rated yet | 0
(Medical Xpress)—According to the World Health Organization, approximately 70 million couples experience infertility worldwide. Current data suggests that nearly one third of infertility disorders are due ...
7 minutes ago | not rated yet | 0
(Medical Xpress)—There is no significant risk directly associated with air travel during pregnancy, even at advanced gestation, says report by the University of Liverpool.
17 minutes ago | not rated yet | 0
To coincide with the broadcast of Jabbed: Love, Fear and Vaccines (SBS ONE, Sunday 26 May at 8.30pm) the first ever national survey on Australian attitudes to vaccination reveals surprising statistics including half of Australians ...
34 minutes ago | not rated yet | 0